Services

Contact Us

BIOVECTRA offers a fully integrated approach to onboarding and executing chemical Active Pharmaceutical Ingredients and biological drug substance projects. We combine scalable and adaptable development services with a proven history of scientific expertise to rapidly move from development to commercial manufacturing, using a phase appropriate method. Risk management and Quality by Design form the basis of our process development strategies.

BIOVECTRA’s project support services include:

  • Rapid process development and optimization
  • Process scale-up and transfer to production facilities 
  • Critical process parameters identification and process characterization
  • Development of process control strategies
  • Pre-clinical, clinical and commercial supply
  • Validation support
Display Logo Biovectra

Process Development

Our process development team has demonstrated experience in process development and characterization, offering phase appropriate solutions. We employ various methodologies such as Quality by Design, scale down modeling and High Throughput testing. This approach allows for rapid optimization while ensuring critical product quality attributes are maintained.

Analytical Development

BIOVECTRA’s analytical services group supports GMP and CMC requirements from early development to validation of commercial processes and continuous process verification, all along the life cycle of your programs. Our capabilities include regulatory-driven, phase-appropriate testing for both small molecules APIs and biologic drug substances. They cover the full scope of method development and validation, as well as formulation development and impurity identification.

Tech Transfer

Our analytical and process development teams work hand-in-hand in the lab with production teams. A dedicated tech transfer team ushers the process to the manufacturing floor, working closely with the processing engineering team to proactively address any challenges. Tight team alignment, dedication to quality at commercial scale, and our commitment to problem-solving facilitate collaboration with clients to solve your increasingly complex problems.

Clinical Development

Our strong technical leaders drive projects throughout product life cycles—from early to commercial stages. They review methods and processes in-depth with our clients’ subject matter experts to map tailored development and commercialization paths, allowing us to improve the likelihood of success. Our nimble, phase-appropriate approach to pre-clinical and clinical material supply enables our clients to move quickly and cost-efficiently through the clinical phases, so that they can deliver therapies to patients faster.

Scale Up

Following an empirically proven method , our dedicated process sciences, process engineering and analytical development teams work together to make scale-up and subsequent validation activities highly effective. By executing exactly what is required to succeed and optimizing the costs, we de-risk our clients’ programs at their most pivotal stage.

Commercial Scale

BIOVECTRA has a proven success story in commercial manufacturing with several established commercial production partnerships. Decades of commercial manufacturing experience enable us to anticipate common production ramp-up problems, address these challenges in the scale-up process, and avoid delays and supply disruptions that impact patients’ lives. Our teams’ tight alignment allows for highly effective collaboration, rapid progress to commercial manufacturing, and increases speed-to-market with the ability to grow with our clients.

“I’m always amazed by the expertise of our process engineering team and their commitment to on-time project delivery. They work under tight timelines to configure the facility and align equipment optimally—all while the process development work is still in progress.”

—Marc Sauer, VP and GM Process Science & Development Services.

“Because we can take products through the entire life cycle, we approach projects with successful commercial manufacturing at the forefront of our minds. From the beginning, our teams collaborate with the client and each other to ensure success at commercial scale.”

— Neil Morrison, Manager, Manufacturing, Technology & Engineering

Ready to learn how BIOVECTRA can help?

Contact us today!

SEO plus – Test

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Normand Blais – Senior Director Development & Innovation, Biologics

  • 20+ years at GSK, leading R&D activities on multiple vaccine programs
  • Recently held positions in industry include: Senior Director (Function Head), Protein Biochemistry; Director, Antigen Design & Prototype Production; and, Associate Director, Antigen Design and Protein Characterization.
  • Key areas of expertise are:
    • Process development of protein Biologics/Recombinant Antigens
    • Recombinant protein expression (mammalian, insect, yeast, bacterial)
    • Production/design of Viral Vectors, mRNA vaccines, Bacterial outer membrane vesicles
    • Protein Engineering and Structural Biology
    • Defining quality attributes, biophysical characterization of proteins, and analytical strategy
  • Post graduate degrees in Functional Genomics (Université Laval) and Bioinformatics (MIT); M. Sc. Microbiology and Immunology (Laval).
  • 25+ Patent & 5 Scientific Publications

Oliver Technow - Chief Executive Officer

  • Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
  • More than 20 years of global pharmaceutical industry experience.
  • Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
  • In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ;  in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
  • Appointed President of BIOVECTRA Inc., December 10, 2015.
  • Board Director for BIOTECanada
  • Member of the Steering Council of Innovative Medicines Canada (IMC)
  • In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
  • In November 2019, promoted to Chief Executive Officer at BIOVECTRA
  • In June 2020, named new Chair of PEI BioAlliance Board of Directors